We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bio-Rad Proposes to Buy BioSource

By Labmedica staff writers
Posted on 21 Apr 2005
A proposal to acquire all of the outstanding shares of BioSource (Camarillo, CA, USA) has been announced by Bio-Rad Laboratories (Hercules, CA, USA).

Bio-Rad made its proposal in the form of a letter to the BioSource board. In the letter, Bio-Rad stated that it has made repeated attempts over the last two years to persuade the BioSource board to enter into negotiations regarding a merger but was rebuffed by the board.

Bio-Rad offered to pay U.S.$8.50 per share in cash for the outstanding shares. The company already owns about 5% of the outstanding shares of BioSource. "The synergies offered by the combination of the product lines and research capabilities of Bio-Rad and BioSource make this an attractive match and will enable us to add value to the BioSource business,” observed Brad Crutchfield, vice president, life sciences, Bio-Rad.

"Our offer represents a 21% premium to BioSource's closing price on April 5, 2005, and a 30% premium to its three-year average closing price,” said Norman Schwartz, president and CEO of Bio-Rad. "We believe this provides an attractive premium and enhanced liquidity for BioSource shareholders.” Based on the closing price on April 6, 2005, BioSource was valued at around $68 million, while the new proposal on April 7, 2005 valued BioSource at over $82 million.




Related Links:
Bio-Rad

Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
All-in-One Molecular System
AIO M160
Automated Coagulation Analyzer
Hemolumi H6

Latest Industry News

Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
21 Apr 2005  |   Industry

Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
21 Apr 2005  |   Industry

Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections
21 Apr 2005  |   Industry



PURITAN MEDICAL